Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 637

1 1. Chudwin DS, Cowan MJ, Greenberg PL, Wara DW, Ammann AJ. Response of agranulocytosis to prolonged antithymocyte globulin therapy. J Pediatr. 1983; 103(2):223–227. doi:10.1016/s0022‐3476(83)80349‐7

2 2. Greenberg PL. The smoldering myeloid leukemic states: clinical and biologic features. Blood. 1983; 61(6):1035–1044.

3 3. Levine E.G. Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992; 19(1):47–84.

4 4. Dahl G, Werner R, Levine E, Rabadan‐Diehl C. Mutational analysis of gap junction formation. Biophys J. 1992; 62(1):172–182. doi:10.1016/S0006‐3495(92)81803‐9

5 5. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML‐‐dysplastic versus proliferative type. Leuk Res. 1998; 22(10):871–878. doi:10.1016/s0145‐2126(97)00192‐6

6 6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088. doi:10.1182/blood.v89.6.2079

7 7. Malcovati L, Hellström‐Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943–2964. doi:10.1182/blood‐2013‐03‐492884

8 8. Knickman JR, Snell EK. The 2030 problem: Caring for aging baby boomers. Health Serv Res. 2002; 37(4):849–884. doi:10.1034/j.1600‐0560.2002.56.x

9 9. Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high‐risk myelodysplastic syndromes (MDS) patients. Ann Hematol. 2012; 91(9):1333–1343. doi:10.1007/s00277‐012‐1472‐8

10 10. Aul C, Gattermann N. The role of low‐dose chemotherapy in myelodysplastic syndromes. Leuk Res. 1992; 16(3):207–215. doi:10.1016/0145‐2126(92)90058‐f

11 11. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: Incidence and survival in the United States. Cancer. 2007; 109(8):1536–1542. doi:10.1002/cncr.22570

12 12. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001‐2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45–52. doi:10.1182/blood‐2008‐01‐134858

13 13. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims‐based algorithm: High number of uncaptured cases by cancer registries. Blood. 2011; 117(26):7121–7125. doi:10.1182/blood‐2011‐02‐337964

14 14. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17):2847–2852. doi:10.1200/JCO.2009.25.2395

15 15. Pedersen‐Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA‐topoisomerase II. Blood. 1991; 78(4):1147–1148.

16 16. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med. 1991; 90(1):338–344. doi:10.1016/0002‐9343(91)90574‐H

17 17. Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol. 1983; 55(2):217–227. doi:10.1111/j.1365‐2141.1983.tb01241.x

18 18. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454–2465. doi:10.1182/blood‐2012‐03‐420489

19 19. della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra‐hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011; 96(3):441–449. doi:10.3324/haematol.2010.033506

20 20. Naqvi K, Garcia‐Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model. J Clin Oncol. 2011; 29(16):2240–2246. doi:10.1200/JCO.2010.31.3353

21 21. Van Spronsen MF, Ossenkoppele GJ, Holman R, Van De Loosdrecht AA. Improved risk stratification by the integration of the revised International Prognostic Scoring System with the Myelodysplastic Syndromes Comorbidity Index. Eur J Cancer. 2014; 50(18):3198–3205. doi:10.1016/j.ejca.2014.09.016

22 22. Daver N, Naqvi K, Jabbour E, et al. Impact of comorbidities by ACE‐27 in the revised‐IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014; 89(5):509–516. doi:10.1002/ajh.23675

23 23. Balleari E, Salvetti C, Del Corso L, et al. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leuk Res. 2015; 39(8):846–852. doi:10.1016/j.leukres.2015.05.007

24 24. Hurria A, Mohile S, Gajra A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol. 2016; 34(20). doi:10.1200/JCO.2015.65.4327

25 25. Van Der Walde N, Jagsi R, Dotan E, et al. Older adult oncology, version 2.2016: Featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2016; 14(11):1357–1370. doi:10.6004/jnccn.2016.0146

26 26. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004; 59(3):255–263. doi:10.1093/gerona/59.3.m255

27 27. Hamaker ME, Schiphorst AH, ten Bokkel Huinink D, Schaar C, van Munster BC. The effect of a geriatric evaluation on treatment decisions for older cancer patients – a systematic review. Acta Oncol (Madr). 2014; 53(3):289–296. doi:10.3109/0284186X.2013.840741

28 28. Cohen HJ, Smith D, Sun CL, et al. Frailty as determined by a comprehensive geriatric assessment‐derived deficit‐accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016; 122(24):3865–3872. doi:10.1002/cncr.30269

29 29. Guerard EJ, Deal AM, Chang Y, et al. Frailty index developed from a cancer‐specific geriatric assessment and the association with mortality among older adults with cancer. JNCCN J Natl Compr Cancer Netw. 2017; 15(7):894–902. doi:10.6004/jnccn.2017.0122

30 30. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: Asco guideline for geriatric oncology. J Clin Oncol. 2018; 36(22):2326–2347. doi:10.1200/JCO.2018.78.8687

31 31. Abel GA, Hshieh TT, Condron NB, et al. Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study. Blood. 2015; 126(23):3306–3306. doi:10.1182/blood.v126.23.3306.3306

32 32. Cesari M, Kritchevsky SB, Penninx BWHJ, et al. Prognostic value of usual gait speed in well‐functioning older people ‐ Results from the health, aging and body composition study. J Am Geriatr Soc. 2005; 53(10):1675–1680. doi:10.1111/j.1532‐5415.2005.53501.x

33 33. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health‐related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009; 57(2):251–259. doi:10.1111/j.1532‐5415.2008.02126.x

34 34. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA ‐ J Am Med Assoc. 2011; 305(1):50–58. doi:10.1001/jama.2010.1923

35 35. Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326–2347. doi:10.1200/JCO.2018.78.8687

36 36. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21):4287–4294. doi:10.1182/blood‐2012‐12‐471680

37 37. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005; 55(3):241–252. doi:10.1016/j.critrevonc.2005.06.003

38 38. Repetto L, Fratino L, Audisio RA, et al. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002; 20(2):494–502. doi:10.1200/JCO.2002.20.2.494

39 39. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4):1582–1587. doi:10.1200/JCO.1998.16.4.1582

40 40. Hurria A, Togawa K, Mohile SG, et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J Clin Oncol. 29:3457–3465. doi:10.1200/JCO.2011.34.7625

41 41. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395. doi:10.1182/blood‐2007‐03‐082404

42 42. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999; 340(21):1649–1660. doi:10.1056/NEJM199905273402107

43 43. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol. 1994; 46(4):270–277. doi:10.1002/ajh.2830460404

44 44. Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Intern Med. 2017; 5(3):139–143. doi:10.1515/jtim‐2017‐0002

45 45. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood‐cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477–2487. doi:10.1056/NEJMoa1409405

46 46. Sanz‐De Pedro M, Wang W, Kanagal‐Shamanna R, Khoury JD. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Curr Hematol Malig Rep. 2018; 13(6):467–476. doi:10.1007/s11899‐018‐0483‐5

47 47. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021–4034. doi:10.1182/blood‐2013‐09‐381665

48 48. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009; 23(5):905–911. doi:10.1038/leu.2009.47

49 49. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289–2301. doi:10.1056/NEJMoa0810069

50 50. Abdel‐Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144–147. doi:10.1182/blood‐2009‐03‐210039

51 51. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147–1152. doi:10.1038/leu.2011.71

52 52. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015; 126(2):233–241. doi:10.1182/blood‐2015‐03‐633537

53 53. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization‐defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674–5677. doi:10.1182/blood‐2012‐03‐415356

54 54. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705–2712. doi:10.1182/blood‐2014‐06‐582809

55 55. Valent P, Horny H, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. 2007; 31:727–736. doi:10.1016/j.leukres.2006.11.009

56 56. Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting ‐ Airlie house, Virginia, November 1997. J Clin Oncol. 1999; 17(12):3835–3849. doi:10.1200/JCO.1999.17.12.3835

57 57. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405. doi:10.1182/blood‐2016‐03‐643544

58 58. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009; 114(5):937–951. doi:10.1182/blood‐2009‐03‐209262

59 59. Greenberg PL, Stone RM, Al‐Kali A, et al. Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2017; 15(1):60–87. doi:10.6004/jnccn.2017.0007

60 60. Montalban‐Bravo G, Garcia‐Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management. Am J Hematol. 2018; 93(1):129–147. doi:10.1002/ajh.24930

61 61. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351–1361. doi:10.1002/cncr.23697

62 62. Malcovati L, Germing U, Kuendgen A, et al. Time‐Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007; 25(23):3503–3510. doi:10.1200/JCO.2006.08.5696

63 63. Fega KR, Abel GA, Motyckova G, et al. Non‐hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015; 6(4):288–298. doi:10.1016/j.jgo.2015.05.003

64 64. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011; 38(5):635–647. doi:10.1053/j.seminoncol.2011.04.014

65 65. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony‐stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400. doi:10.1182/blood‐2009‐03‐211797

66 66. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte‐colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26(21):3607–3613. doi:10.1200/JCO.2007.15.4906

67 67. Buckstein R, Balleari E, Wells R, et al. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. Am J Hematol. 2017; 92(10):1037–1046. doi:10.1002/ajh.24842

68 68. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010; 28(33):4996–5010. doi:10.1200/JCO.2010.29.2201

69 69. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116(20):4045–4059. doi:10.1182/blood‐2010‐08‐300541

70 70. Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo‐controlled trial of darbepoetin alfa in patients with anemia and lower‐risk myelodysplastic syndromes. Leukemia. 2017; 31(9):1944–1950. doi:10.1038/leu.2017.192

71 71. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo‐controlled study assessing the efficacy and safety of epoetin‐α in anemic patients with low‐risk MDS. Leukemia. 2018; 32(12):2648–2658. doi:10.1038/s41375‐018‐0118‐9

72 72. Hellström‐Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89(1):67–71. doi:10.1111/j.1365‐2141.1995.tb08909.x

73 73. Hellström‐Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: Significant effects on quality of life. Br J Haematol. 2003; 120(6):1037–1046. doi:10.1046/j.1365‐2141.2003.04153.x

74 74. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‐CSF: The GFM experience. Blood. 2008; 111(2):574–582. doi:10.1182/blood‐2007‐06‐096370

75 75. J.R. W, Y.C. U, J.A. J, et al. Randomized, double‐blind, placebo‐controlled trial of erythropoietin in non‐small‐cell lung cancer with disease‐related anemia. J Clin Oncol. 2007; 25(9):1027–1032. doi:10.1200/JCO.2006.07.1514 LK ‐ http://WT3CF4ET2L.search.serialssolutions.com?sid=EMBASE&issn=0732183X&id=doi:10.1200%2FJCO.2006.07.1514&atitle=Randomized%2C+double‐blind%2C+placebo‐controlled+trial+of+erythropoietin+in+non‐small‐cell+lung+cancer+with+disease‐related+anemia&stitle=J.+Clin.+Oncol.&title=Journal+of+Clinical+Oncology&volume=25&issue=9&spage=1027&epage=1032&aulast=Wright&aufirst=James+R.&auinit=J.R.&aufull=Wright+J.R.&coden=JCOND&isbn=&pages=1027‐1032&date=2007&auinit1=J&auinitm=R

76 76. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study. J Clin Oncol. 2008; 26(7):1040–1050. doi:10.1200/JCO.2007.14.2885

77 77. Jädersten M, Montgomery SM, Dybedal I, Porwit‐MacDonald A, Hellström‐Lindberg E. Long‐term outcome of treatment of anemia in MDS with erythropoietin and G‐CSF. Blood. 2005; 106(3):803–811. doi:10.1182/blood‐2004‐10‐3872

78 78. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47–61. doi:10.1182/asheducation‐2001.1.47

79 79. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol. 2003; 509:91–125. doi:10.1007/978‐1‐4615‐0593‐8_6

80 80. Messa E, Cilloni D, Saglio G. Iron Chelation Therapy in Myelodysplastic Syndromes. Adv Hematol. 2010; 2010. doi:10.1155/2010/756289

81 81. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron‐overloaded patients with transfusion‐dependent myelodysplastic syndromes: Results from the large 1‐year EPIC study. Leuk Res. 2010; 34(9):1143–1150. doi:10.1016/j.leukres.2010.03.009

82 82. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83(11):858–861. doi:10.1002/ajh.21269

83 83. Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol. 2008; 88(1):30–35. doi:10.1007/s12185‐008‐0119‐y

84 84. Mittelman M, Lugassy G, Merkel D, et al. Iron chelation therapy in patients with myelodysplastic syndromes: Consensus conference guidelines. Isr Med Assoc J. 2008; 10(5):374–376.

85 85. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120(2):187–200. doi:10.1046/j.1365‐2141.2003.03907.x

86 86. Slichter SJ. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337(26):1861–1869. doi:10.1056/NEJM199712253372601

87 87. Syndromes ICSG for rHuEpo in M, Ferrini PR, Grossi A, et al. A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes. Br J Haematol. 1998; 103(4):1070–1074.

88 88. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion‐dependent patients with Low‐/Intermediate‐1‐risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765–3776. doi:10.1182/blood‐2011‐01‐330126

89 89. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion‐dependent patients with lower‐risk non‐del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis‐stimulating agents. J Clin Oncol. 2016; 34(25):2988–2996. doi:10.1200/JCO.2015.66.0118

90 90. Schiffer CA, Miller K, Larson RA, et al. A double‐blind, placebo‐controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000; 95(8):2530–2535. doi:10.1182/blood.v95.8.2530.008k31_2530_2535

91 91. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double‐blind, placebo‐controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999; 94(11):3694–3701.

92 92. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low‐dose interleukin‐11 in patients with bone marrow failure. J Clin Oncol. 2001; 19(21):4165–4172. doi:10.1200/JCO.2001.19.21.4165

93 93. Kuter DJ, Bussel JB, Lyons RM, et al. Effi Cacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: A Double‐Blind Randomised Controlled Trial. Vol 371.; 2008.

94 94. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010; 28(3):437–444. doi:10.1200/JCO.2009.24.7999

95 95. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163–3170. doi:10.1182/blood‐2010‐03‐274753

96 96. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, non‐peptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739–4741. doi:10.1182/blood‐2006‐11‐057968

97 97. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429–2440. doi:10.1200/JCO.2002.04.117

98 98. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncol. 2009; 10(3):223–232. doi:10.1016/S1470‐2045(09)70003‐8

99 99. Lübbert M, Suciu S, Baila L, et al. Low‐dose decitabine versus best supportive care in elderly patients with intermediate‐ or high‐risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the european organisation for rese. J Clin Oncol. 2011; 29(15):1987–1996. doi:10.1200/JCO.2010.30.9245

100 100. Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016; 175(5):829–840. doi:10.1111/bjh.14305

101 101. Prébet T, Gore SD, Esterni B, et al. Outcome of high‐risk myelodysplastic syndrome after azacitidine Treatment failure. J Clin Oncol. 2011; 29(24):3322–3327. doi:10.1200/JCO.2011.35.8135

102 102. Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017; 130(9):1156–1164. doi:10.1182/blood‐2017‐03‐772368